It has been found that Raloxifene, a drug used to prevent and treat postmenopausal women’s osteoporosis, can inhibit NETs production by targeting nuclear estrogen receptors ERα and ERβ (Muchmore, 2000; Hansdóttir, 2008; Flores et al., 2016). This evidence concerns the gene ESR1 and osteoporosis.